Premium
Cinacalcet: A New Treatment for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Author(s) -
Byrnes Cecelia A.,
Shepler Brian M.
Publication year - 2005
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.25.5.709.63595
Subject(s) - cinacalcet , calcimimetic , secondary hyperparathyroidism , medicine , parathyroid hormone , hyperparathyroidism , vitamin d and neurology , population , kidney disease , drug , hemodialysis , clinical trial , urology , pharmacology , calcium , environmental health
Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. A literature search, performed by using PubMed and MEDLINE from January 1997–June 2004, identified articles concerning the efficacy and safety of cinacalcet in this patient population. Currently, Vitamin D and its analogs are considered first‐line therapy for secondary hyperparathyroidism. However, use of these agents is often accompanied by an increase in serum calcium and phosphorus concentrations, a problem that often limits their use. Cinacalcet's mechanism of action decreases parathyroid hormone, calcium, and phosphorus levels, offering potential advantages over the other treatments for secondary hyperparathyroidism. Additional clinical trials are needed to evaluate the long‐term safety and efficacy of the drug as a first‐line agent.